TWiV 845: COVID-19 clinical update #94 with Dr. Daniel Griffin
Dec 25, 2021•48 min•Ep. 845
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In COVID-19 clinical update #94, Daniel Griffin reviews the FDA EUA for Paxlovid, test to stay in school, immunity after infection, variants and therapeutics, quarantine and isolation guidelines, Molnupiravir in non-hospitalized patients, and convalescent serum in outpatients.
Hosts: Daniel Griffin and Vincent RacanielloSubscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- FDA EUA for Paxlovid (pdf)
- Children and COVID-19 (pdf)
- Evaluation of test to stay in school, IL (MMWR)
- Evaluation of test to stay in school, LA (MMWR)
- Update on mRNA vaccine in under 5 yo (Pfizer)
- CDC endorses preference for mRNA vaccines (CDC)
- Natural immunity and protection against delta (Clin Inf Dis)
- Cross-neutralization post-vaccination infection (JAMA)
- Variants and therapeutics (NIH)
- Quarantine and isolation (CDC)
- Molnupiravir in non-hospitalized patients (NEJM)
- Convalescent serum for outpatients (medRxiv)
- Letters read on TWiV 845
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkee
Send your questions for Dr. Griffin to daniel@microbe.tv
For the best experience, listen in Metacast app for iOS or Android